Drug-induced megaloblastic change.
D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D004247:DNA / Q000096:biosynthesis; D004913:Erythrocytes, Abnormal / Q000187:drug effects*; D005467:Floxuridine / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects; D005493:Folic Acid Antagonists; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects; D008534:Megaloblasts / Q000187:drug effects*; D008727:Methotrexate / Q000009:adverse effects; D010672:Phenytoin / Q000009:adverse effects; D011739:Pyrimethamine / Q000009:adverse effects; D012265:Ribonucleotides / Q000378:metabolism; D013938:Thymidine Monophosphate / Q000096:biosynthesis; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014223:Triamterene / Q000009:adverse effects; D014295:Trimethoprim / Q000009:adverse effects
D005493:Folic Acid Antagonists; D012265:Ribonucleotides; D005467:Floxuridine; D003561:Cytarabine; D013938:Thymidine Monophosphate; D010672:Phenytoin; D003520:Cyclophosphamide; D004247:DNA; D014295:Trimethoprim; D013940:Thymidylate Synthase; D005472:Fluorouracil; D014223:Triamterene; D006918:Hydroxyurea; D008727:Methotrexate; D011739:Pyrimethamine